Table 1.
Guideline | Criteria |
SCG | |
MD-IPMN | MPD ≥ 10 mm |
SCG+ve BD-IPMN | Size > 3 cm |
Size ≤ 3 cm with symptoms/mural nodules/MPD dilation (> 6 mm)/ positive cytology | |
FCG | |
High risk features | Proximal lesion with obstructive jaundice |
Enhancing nodules | |
Dilated main duct (≥ 10 mm) | |
Worrisome risk features | Size ≥ 3 cm |
Pancreatitis | |
Non-enhancing nodules | |
Thickened, enhancing walls | |
Dilated duct (5 to < 10 mm) | |
Change in duct caliber with distal atrophy | |
Lymphadenopathy |
FCG: Fukuoka; SCG: Sendai Consensus Guidelines; MPD: Main pancreatic duct; MD-IPMN: Main-duct intraductal papillary mucinous neoplasm; BD-IPMN: Branch-duct intraductal papillary mucinous neoplasm.